Silas Inman | Authors

FDA Grants Fast Track Designation to CYNK-101 for HER2+ Gastric/GEJ Cancers

January 18, 2022

CYNK-101 plus standard frontline chemotherapy, trastuzumab, and pembrolizumab has received a fast track designation from the FDA for patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Phase 3 Study Explores Pamrevlumab for Unresectable LAPC

February 17, 2021

The first-in-class inhibitor of connective tissue growth factor activity is being explored in combination with neoadjuvant gemcitabine and nab-paclitaxel as a potential method for downgrading unresectable locally advanced pancreatic cancer.